Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

NCT00529529 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

805

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: Indacaterol 300 μg
DRUG: Salmeterol 50 μg
DRUG: Placebo to indacaterol
DRUG: Placebo to salmeterol

Sponsor

Novartis Pharmaceuticals